Clinical trials
HPV clinical trials
Below are recruiting hpv clinical trials, each written for real people, not researchers. We’re tracking 259 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06810739Recruiting
Women's Screening and Self-Testing Program (PROMETA)
This study tests a self-screening program for cervical cancer among women who are already receiving HIV care. It aims to make screening easier and more accessible.
MaputoAges 25–49 - NCT06662058Recruiting
Remote hearing test for head and neck cancer patients on cisplatin or radiation
This study tests a remote hearing test to monitor hearing changes in patients with head and neck cancer getting cisplatin chemotherapy and/or radiation. The goal is to catch hearing loss early so treatment can be adjusted.
Atlanta, GeorgiaAges 18 years+ - NCT07179315RecruitingPhase 2
Immunotherapy Study for HPV-Positive Head and Neck Cancer
This trial compares two different immunotherapy approaches for people with HPV-positive oropharyngeal cancer who have completed initial treatment like surgery, radiation, or chemotherapy. The goal is to see which option works better to keep the cancer from coming back, and eligibility is determined by a special blood test that detects HPV DNA.
Chicago, IllinoisAges 18 years+ - NCT05799144RecruitingPhase 2
Pembrolizumab plus investigational HPV drugs for throat cancer
This Phase 2 trial studies pembrolizumab (an immune therapy) combined with investigational treatment(s) pBI-11 and TA-HPV for advanced or recurrent oropharyngeal cancer that is HPV-positive and has certain immune marker levels (PD-L1 CPS ≥ 1). It may help your immune system better attack cancer.
Birmingham, AlabamaAges 18 years+ - NCT03061435Recruiting
Screening for anal cancer after high-grade vulvar changes
This trial checks whether anal cancer screening is useful for women age 40 and older who previously had high-grade vulvar pre-cancer (VIN 2/3) or vulvar cancer. It may help find serious problems earlier in people at higher risk.
Toronto, OntarioAges 40 years+ - NCT03396718Recruiting
De-escalating radiation after HPV head and neck cancer surgery
This study looks at whether some people with HPV-positive throat/oropharynx cancer can safely receive a less intense form of radiation (and sometimes chemo) after surgery. It aims to reduce treatment burden while keeping the cancer under control, based on how high-risk the pathology looks.
Tübingen, Baden-WurttembergAges 18 years+ - NCT03853915Recruiting
PET scan and HPV testing during chemoradiation for cervical cancer
This study looks at whether a PET scan (FDG-PET/CT) and blood HPV testing can help track cervical cancer responses during and after standard chemo-radiation. It may help doctors better understand who is responding and who may need different care.
Toronto, OntarioAges 18 years+ - NCT03875716Recruiting
De-intensified radiation after surgery for HPV throat cancer
This trial studies a lower-intensity (less aggressive) course of radiation therapy after curative surgery for HPV-related tonsil or base-of-tongue cancer. The goal is to see if patients can still be treated successfully while reducing side effects from radiation.
Boston, MassachusettsAges 18 years+ - NCT04057924Recruiting
Watchful waiting for certain abnormal cells in the cervix
This trial checks whether “therapy abstention” (not treating right away) and close monitoring is safe for certain high-grade cervical cell changes. It may help some people avoid immediate procedures while still catching any progression early.
BordeauxAges 18 years+ - NCT04220749RecruitingPhase 2
Radiation vs mouth surgery for HPV-negative throat cancer
This Phase 2 trial compares two standard cancer treatments—radiation or surgery through the mouth—for HPV-negative oropharyngeal throat cancer. It aims to find out which approach works better while keeping side effects and quality of life acceptable.
London, OntarioAges 18 years+ - NCT04422366RecruitingPhase 3
9-valent HPV vaccine study for healthy Chinese women
This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.
Liuzhou, GuangxiAges 20–45 - NCT04564989Recruiting
Biomarker study for HPV-related throat cancer outcomes
This observational study checks how well a blood test for HPV DNA (and other tumor genetic markers) predicts outcomes in certain throat cancers. It may help doctors better track the disease and plan treatment, because the trial validates these lab signals against real-world results.
Rochester, MinnesotaAges 18 years+ - NCT04681469RecruitingPhase 2
Niraparib plus immunotherapy for HPV-negative head and neck cancer
This Phase 2 study tests a cancer “induction then maintenance” plan using a PARP inhibitor (niraparib) along with immunotherapy (TSR-042) in people with HPV-negative head and neck squamous cell cancer. If it works, it may improve control of the cancer after surgery by boosting the immune system and targeting cancer cells’ DNA repair.
BresciaAges 18 years+ - NCT04814446RecruitingPhase 3
Vaccine trial for stubborn warts on hands or feet
This Phase 3 trial tests a nonavalent HPV vaccine to treat long-lasting, hard-to-treat warts on the hands or feet. If you have tried standard treatments and the warts keep coming back or cause trouble, the vaccine may help your body clear the warts.
ParisAges 15 years+ - NCT04859530Recruiting
Smartphone AI test for cervical cancer screening
This study checks whether a smartphone-based AI tool can help screen for cervical cancer. You may be offered the AI-assisted screening during a clinic visit to see if it works well when visualizing the cervix.
Dschang, MenouaAges 30–49 - NCT05026138Recruiting
Study of severe HPV disease and why it keeps coming back
This study follows people with severe or hard-to-treat HPV-related conditions (and some closely related partners/household contacts) to learn how the virus causes illness and how the immune system responds. It may help doctors better predict who will develop severe disease and guide future treatments.
Bethesda, MarylandAges 3–100 - NCT05266898RecruitingPhase 4
HPV vaccine response study for people living with HIV
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
New Orleans, LouisianaAges 18–65 - NCT05317000RecruitingPhase 2
Testing a new treatment plan for HPV throat cancer before surgery
This Phase 2 trial studies whether 5-azacytidine and nivolumab (alone and/or together) can work well and be tolerated in people with HPV-related throat cancer that can be surgically removed. The goal is to help shrink or control the cancer before resection and learn more from added tumor samples.
New Haven, ConnecticutAges 18 years+ - NCT05336240Recruiting
Parent-teen communication coaching for ages 9–17
This study tests a communication coaching program for parents to help them talk with their teen. It targets families with teens ages 9–17 receiving care at participating clinics.
Aurora, ColoradoAges 9–17 - NCT05539638Recruiting
Testing blood DNA for head and neck squamous cancer
This study looks at how tumor DNA found in a blood sample (a “DNA signal”) relates to head and neck cancer in the oropharynx. It may help doctors understand disease status and improve how they monitor treatment, for both HPV-positive and HPV-negative cancers.
Dundee, DD2 1SGAges 18 years+ - NCT05572801Recruiting
Tumor DNA blood tests to guide follow-up after anal cancer
This study tests whether regular blood tests looking for “tumor DNA” can help guide your follow-up care after anal cancer treatment. It may help doctors decide what type of monitoring you need during check-ups.
Herlev, Capital Region of DenmarkAges 18 years+ - NCT05576831Recruiting
Testing HPV and p53 to guide vulvar cancer surgery
This study looks at two tumor test results—HPV and p53—to help doctors decide how much tissue to remove during surgery for vulvar squamous cell carcinoma. It’s meant to reduce the risk of the cancer coming back while avoiding unnecessary removal when margins are only close.
Vancouver, British ColumbiaAges 18 years+ - NCT05582122RecruitingPhase 2
Tracking HPV16 DNA in blood to spot cancer coming back
This study checks whether a blood test for HPV16 DNA can predict when HPV-related throat cancer comes back after treatment. It may help improve follow-up care by catching recurrence earlier.
Saint-Denis, La RéunionAges 18 years+ - NCT05606133Recruiting
Test HPV DNA from blood to track cervical cancer risk
This study looks at a blood test that measures HPV DNA to help screen and monitor people with HPV-related cervical problems. If you have confirmed high-grade cervical changes or cervical cancer, the test may help doctors follow how your condition changes over time.
New York, New YorkAges 18 years+
Hear when a new HPV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hpv?
- Yes. Clin2 currently lists 259 recruiting hpv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hpv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hpv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.